Text this: Comment on “Major adverse cardiac and cerebrovascular events (MACCEs) in patients with acute ST-segment elevation myocardial infarction (STEMI) treated with pharmaco-invasive strategy of half-dose recombinant human prourokinase (PHDP): Two-year outcomes”